Great issue, esp the article by @LImmunotherapy and @AlfredZippelius on immune therapies that target the TME in general and sialoglycan/Siglec axis in particular, some of the more promising candidates in the pipeline. #glycotime @Palleon_Pharma @InterVennBioSci